Sage Therapeutics Inc (SAGE)
11.40
-0.60
(-5.00%)
USD |
NASDAQ |
Jun 17, 14:29
Sage Therapeutics SG&A Expense (Annual): 274.52M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 274.52M |
| December 31, 2022 | 227.70M |
| December 31, 2021 | 183.50M |
| December 31, 2020 | 196.95M |
| December 31, 2019 | 345.78M |
| December 31, 2018 | 201.40M |
| Date | Value |
|---|---|
| December 31, 2017 | 62.88M |
| December 31, 2016 | 39.41M |
| December 31, 2015 | 25.29M |
| December 31, 2014 | 9.71M |
| December 31, 2013 | 3.922M |
| December 31, 2012 | 2.402M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
183.50M
Minimum
2021
345.78M
Maximum
2019
245.69M
Average
227.70M
Median
2022
SG&A Expense (Annual) Benchmarks
| Biogen Inc | 2.550B |
| Vanda Pharmaceuticals Inc | 112.88M |
| Ligand Pharmaceuticals Inc | 52.79M |
| ADMA Biologics Inc | 59.02M |
| Axsome Therapeutics Inc | 323.12M |